Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
At a glance
- Drugs XT-150 (Primary)
- Indications Osteoarthritis; Pain
- Focus Adverse reactions
- Sponsors Xalud Therapeutics
- 16 Jan 2019 Planned End Date changed from 1 Aug 2019 to 1 Sep 2019.
- 16 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2018 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.